The Health Effect of Diet Rich in Nordic Berries

Metabolic Syndrome Clinical Trial

— Berry  

Official title:

The Effect of Diet Rich in Nordic Berries on Gut Microbiota, Glucose and Lipid Metabolism and Metabolism on Fenolic Compounds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01414647
• Other study ID #: 124//2005
• Secondary ID: 40361/05
• Status: Completed
• Phase: N/A
• Start date: January 2006
• Est. completion date: March 2010

Study information

• Verified date: May 2018
• Source: University of Eastern Finland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dietary polyphenols might have beneficial effects on glucose and lipid metabolism based on the studies made in animals or cell cultures. The findings regarding the possible decrease of low-grade inflammation are existing also in humans. Low-grade inflammation has been suggested to be a mechanistic link between obesity and its consequences on cardiometabolic health. The aim of the present study is to examine the effect of diet rich in berries on glucose and lipid metabolism and inflammatory markers.

Description:

Berries are traditionally an important part of the Nordic diet. About 50 different berries are grown in the northern region, and about half of them are edible. Phenolic compounds are one of the most diverse group of secondary metabolites present in edible plants, and berries are especially rich in them. Flavonoids, phenolic acids, lignans and complex phenolic polymers (polymeric tannins) are typical for berries. Phenolic compounds are reported to have a variety of beneficial biological properties. They are potent antioxidants, and exhibit various other physiological activities including anti-inflammatory, antimicrobial, antiallergic, anticarcinogenic and antihypertensive activities. Epidemiological studies indicate that diet rich in phenolic compound correlates with lower risk of cancer and cardiovascular disease.

The aim of the present study is to examine the effect of diet rich in berries on glucose and lipid metabolism and inflammatory markers and gene expression profile in peripheral blood mononuclear cells (PBMCs) in subjects with features of metabolic syndrome.

Randomized, controlled clinical intervention including 4 wk run-in period, 8 wk dietary intervention and 4 wk recovery period was conducted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: March 2010
• Est. primary completion date: December 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 65 Years

Eligibility

Inclusion Criteria:

• overweight (BMI 26-39 kg/m2), and two of the following:

• elevated fasting plasma glucose in the absence of diabetes (5.6-6.9 mmol/l)

• abnormal serum lipid concentration: fasting serum triglyceride concentration >1.7 mmol/L, fasting serum HDL cholesterol <1.0 mmol/L (males) or <1.3 mmol/L (females))

• waist circumference >102 cm (males) or >88 cm (females)

• blood pressure >130/85 mmHg

Exclusion Criteria:

• chronic diseases

• use of lipid lowering medication

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias
• Glucose Intolerance
• Impaired Glucose Tolerance
• Inflammation
• Low-grade Inflammation
• Metabolic Syndrome
• Metabolic Syndrome X

Intervention

Dietary Supplement:
• 300 g of strawberry, raspberry and cloudberry
100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
• 400 g of bilberry
Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.

Other:
• Control diet
Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks

Locations

Country	Name	City	State
Finland	University of Eastern Finland, Dpet of Public Health and Clinical Nutrition	Kuopio

Sponsors (2)

Lead Sponsor	Collaborator
Marjukka Kolehmainen	VTT Technical Research Centre, Finland

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose level	Fasting glucose level oral glucose tolerance status at study week 8	week 8
Primary	Cholesterol level	total, HDL and LDL cholesterol level at the study week 8	week 8
Primary	Inflammation markers	Various inflammation markers were measured at the study week 8	week 8
Secondary	Markers of sterol metabolism	Markers of cholesterol absorption and synthesis were measured	week 8
Secondary	gene expression in PBMCs	Global gene expression analyses in peripheral mononuclear cells (PBMC)	study week 8